Adalimumab in Treating Refractory Livedoid Vasculopathy

Livedoid vasculopathy is a chronic, recurrent skin disorder. It seriously affects the quality of patients' life. However, the pathogenesis has not been fully identified yet. Here, this retrospective study describes the successful use of anti-TNF-alpha agent adalimumab in three cases of refractory livedoid vasculopathy, which has not been reported previously. In addition, we provide some clinical evidence that adalimumab therapy is efficient in improving skin lesions and relieving the pain of livedoid vasculopathy.

Automated summary

This retrospective study describes the successful use of the anti-TNF-alpha agent adalimumab in three cases of refractory livedoid vasculopathy and provides clinical evidence of its ability to improve skin lesions and relieve pain.